Down regulation of the high-affinity IgE receptor associated with successful treatment of chronic idiopathic urticaria with omalizumab.
Chronic idiopathic urticaria is a condition that is often controllable with antihistamine therapy. However, some patients have disease burden that is difficult to manage, non-responsive to antihistamines and often requires immunosuppressive medications such as corticosteroids or cyclosporine. We present here a study that demonstrates the effectiveness of omalizumab in treating this condition and the temporal relationship between improvement and down regulation of the high affinity IgE receptor (FcεRI). For this, blood samples were obtained from a symptomatic patient before each treatment and processed for flow cytometric analysis of FcεRI levels on the surface of blood basophils. Down regulation of FcεRI was observed in association with significant clinical improvement and discontinuation of immunosuppressive medications.
Division of Allergy, Pulmonary, Immunology, Critical Care and Sleep, Department of Medicine, The University of Texas Medical Branch, 301 University Boulevard, Galveston, Texas, 77555, USA. arizonaallergy@gmail.com.
Michael C
MC
Saavedra
Sanjiv
S
Sur
J Immunol. 1997 Feb 1;158(3):1438-45
9013989
J Allergy Clin Immunol. 2001 Aug;108(2):184-90
11496232
J Allergy Clin Immunol. 2000 Apr;105(4):664-72
10756214
Nat Rev Immunol. 2002 Oct;2(10):773-86
12360215
J Allergy Clin Immunol. 2008 Sep;122(3):569-73
18774392
Eur J Dermatol. 2006 Jul-Aug;16(4):402-5
16935798
J Allergy Clin Immunol. 2004 Sep;114(3):527-30
15356552
J Allergy Clin Immunol. 2004 Sep;114(3):465-74; quiz 475
15356542
Ann Allergy Asthma Immunol. 2007 Aug;99(2):190-3
17718108
J Allergy Clin Immunol. 2004 Feb;113(2):297-302
14767445